51167-135-01 : NDC 2026 Code

51167-135-01 : Vanzacaftor, Tezacaftor, And Deutivacaftor ( Alyftrek )

Additionally :

You can get information about “51167-135-01” NDC code in 51167-135-01 in HTML format

HTML | 51167-135-01 in TXT (Plain Text) format

TXT | 51167-135-01 in PDF (Portable Document Format)

PDF | 51167-135-01 in XML format

XML formats.

NDC Code : 51167-135-01 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "51167-135-01",
    "PackageDescription": "4 BLISTER PACK in 1 CARTON (51167-135-01)  / 21 TABLET, FILM COATED in 1 BLISTER PACK",
    "NDC11Code": "51167-0135-01",
    "ProductNDC": "51167-135",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Alyftrek",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Vanzacaftor, Tezacaftor, And Deutivacaftor",
    "DosageFormName": "TABLET, FILM COATED",
    "RouteName": "ORAL",
    "StartMarketingDate": "20241220",
    "EndMarketingDate": null,
    "MarketingCategoryName": "NDA",
    "ApplicationNumber": "NDA218730",
    "LabelerName": "Vertex Pharmaceuticals Incorporated",
    "SubstanceName": "DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR",
    "StrengthNumber": "50; 20; 4",
    "StrengthUnit": "mg/1; mg/1; mg/1",
    "Pharm_Classes": "Breast Cancer Resistance Protein Inhibitors [MoA], Chloride Channel Activation Potentiators [MoA], Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC], Cytochrome P450 2C9 Inhibitors [MoA], P-Glycoprotein Inhibitors [MoA]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2025-10-03",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "20241220",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}